摘要
低分化甲状腺癌（PDTC）是甲状腺癌中少见的病理亚型，其形态学特征和生物学行为介于分化型甲状腺癌与未分化甲状腺癌之间。PDTC 具有较高侵袭性，易发生复发与转移，目前其诊断标准尚未统一，国际上多采用“都灵标准”。腺外侵袭及远处转移是影响 PDTC 预后的独立危险因素。当前关于 PDTC 的治疗策略尚缺乏一致意见，手术仍为主要治疗方式，而放射性碘治疗、外照射治疗及靶向治疗等辅助治疗方法的疗效仍存在争议。
Abstract
Poorly differentiated thyroid carcinoma (PDTC) is a rare pathological subtype of thyroid carcinoma whose morphological characteristics and biological behavior are intermediate between differentiated thyroid carcinoma and anaplastic carcinoma. PDTC is highly invasive, and is prone to recurrence and metastasis. Its diagnostic criteria are not yet unified, and the“Turin Criteria”are widely adopted internationally. Extrathyroidal invasion and distant metastasis are independent risk factors affecting the prognosis of PDTC. Currently, there is no consensus on the treatment strategies for PDTC. Surgery is the primary treatment modality for PDTC, while adjuvant therapies such as radioactive iodine therapy, external beam radiation therapy, and targeted therapy remain controversial.
关键词
低分化甲状腺癌 /
诊断标准 /
腺外侵袭 /
远处转移 /
分子检测 /
手术治疗 /
放射性碘治疗 /
靶向治疗
Key words
poorly differentiated thyroid carcinoma /
diagnostic criteria /
extrathyroidal invasion /
distant metastasis /
molecular testing /
surgical treatment /
radioactive iodine therapy /
targeted therapy
黄加鹏, 关钰舰, 张 浩.
低分化甲状腺癌诊治策略[J]. 中国实用外科杂志. 2025, 45(09): 1001-1004 https://doi.org/10.19538/j.cjps.issn1005-2208.2025.09.07
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
参考文献
［1］ World Health Organization, DeLellis RA, International Agency for Research on Cancer, et al. Pathology and genetics of tumours of endocrine organs［M］. Lyon: IARC Press, 2004.
［2］ Volante M，Collini P，Nikiforov YE，et al.Poorly differentiated thyroid carcinoma: The Turin proposal for the use of uniform diagnostic criteria and an algorithmic diagnostic approach［J］.Am J Surg Pathol，2007，31（8）:1256-1264.DOI:10.1097/PAS.0b013e3180309e6a.
［3］ Hiltzik D，Carlson DL，Tuttle RM，et al.Poorly differentiated thyroid carcinomas defined on the basis of mitosis and necrosis: A clinicopathologic study of 58 patients［J］.Cancer，2006，106（6）:1286-1295.DOI:10.1002/cncr.21739.
［4］ Gnemmi V，Renaud F，Do Cao C，et al.Poorly differentiated thyroid carcinomas: Application of the Turin proposal provides prognostic results similar to those from the assessment of high-grade features［J］.Histopathology，2014，64（2）:263-273.DOI:10.1111/his.12246.
［5］ Baloch ZW，Asa SL，Barletta JA，et al.Overview of the 2022 WHO classification of thyroid neoplasms［J］.Endocr Pathol，2022，33（1）:27-63.DOI:10.1007/s12022-022-09707-3.
［6］ Cirello V，Gambale C，Nikitski AV，et al.Poorly differentiated thyroid carcinoma: Molecular，clinico-pathological hallmarks and therapeutic perspectives［J］.Panminerva Med，2024，66（2）:155-173.DOI:10.23736/S0031-0808.23.05040-1.
［7］ Huang J，Sun W，Zhang Q，et al.Clinicopathological characteristics and prognosis of poorly differentiated thyroid carcinoma diagnosed according to the turin criteria［J］.Endocr Pract，2021，27（5）:401-407.DOI:10.1016/j.eprac.2020.11.008.
［8］ Saglietti C，Onenerk AM，Faquin WC，et al.FNA diagnosis of poorly differentiated thyroid carcinoma.A review of the recent literature［J］.Cytopathology，2017，28（6）:467-474.DOI:10.1111/cyt.12497.
［9］ Coca-Pelaz A，Rodrigo JP，Agaimy A，et al.Poorly differentiated thyroid carcinomas: Conceptual controversy and clinical impact［J］.Virchows Arch，2024，484（5）:733-742.DOI:10.1007/s00428-024-03752-5.
［10］ Cracolici V，Cipriani NA.High-grade non-anaplastic thyroid carcinomas of follicular cell origin: A review of poorly differentiated and high-grade differentiated carcinomas［J］.Endocr Pathol，2023，34（1）:34-47.DOI:10.1007/s12022-023-09752-6.
［11］ Wong KS，Dong F，Telatar M，et al.Papillary thyroid carcinoma with high-grade features versus poorly differentiated thyroid carcinoma: An analysis of clinicopathologic and molecular features and outcome［J］.Thyroid，2021，31（6）:933-940.DOI:10.1089/thy.2020.0668.
［12］ Hahn SY，Shin JH.Description and comparison of the sonographic characteristics of poorly differentiated thyroid carcinoma and anaplastic thyroid carcinoma［J］.J Ultrasound Med，2016，35（9）:1873-1879.DOI:10.7863/ultra.15.09058.
［13］ Kim JY，Myung JK，Kim S，et al.Prognosis of poorly differentiated thyroid carcinoma: A systematic review and meta-analysis［J］.Endocrinol Metab(Seoul)，2024，39（4）:590-602.DOI:10.3803/EnM.2024.1927.
［14］ Chatterjee S，Mair M，Shaha AR，et al.Current evidences in poorly differentiated thyroid carcinoma: A systematic review and subsection meta-analysis for clinical decision making［J］.Endocrine，2024，85（2）:509-519.DOI:10.1007/s12020-024-03771-x.
［15］ Sonavane SN，Basu S.Role of PET/computed tomography in elderly thyroid cancer: Tumor biology and clinical management［J］.PET Clin，2023，18（1）:81-101.DOI:10.1016/j.cpet.2022.09.005.
［16］ 张大林, 董文武, 张浩. 2024年版日本《甲状腺肿瘤诊疗指南》外科治疗部分更新解读［J］. 中国实用外科杂志, 2025, 45(1): 42-47. DOI:10.19538/j.cjps.issn1005-2208.2025.01.06.
［17］ 苏艳军, 彭颖, 董治中, 等. 2025 版《中国肿瘤整合诊治指南（CACA）—甲状腺癌》系统解读［J］. 中国普通外科杂志, 2025, 34(5): 867-878. DOI:10.7659/j.issn.1005-6947.250270.
［18］ Alam IS，Patel KN.Management of poorly differentiated thyroid cancer and differentiated high-grade thyroid carcinoma［J］.Surg Clin North Am，2024，104（4）:751-765.DOI:10.1016/j.suc.2024.02.005.
［19］ Xu L，Zou Q，Jiao J，et al.Postoperative radioiodine therapy impact on survival in poorly differentiated thyroid carcinoma: A population-based study［J］.Nucl Med Commun，2022，43（2）:145-151.DOI:10.1097/MNM.0000000000001499.
［20］ Patel KN，Shaha AR.Poorly differentiated thyroid cancer［J］.Curr Opin Otolaryngol Head Neck Surg，2014，22（2）:121-126.DOI:10.1097/MOO.0000000000000037.
［21］ Zhang M，Lei S，Chen Y，et al.The role of lymph node status in cancer-specific survival and decision-making of postoperative radiotherapy in poorly differentiated thyroid cancer: A population-based study［J］.Am J Transl Res，2021，13（1）:383-390.PMID: 33527032.
［22］ Roque J，Nunes Silva T，Regala C，et al.Outcomes of lenvatinib therapy in poorly differentiated thyroid carcinoma［J］.Eur Thyroid J，2023，12（2）:e230003.DOI:10.1530/ETJ-23-0003.
［23］ Elghawy O，Barsouk A，Xu J，et al.Real world outcomes of cabozantinib therapy in poorly differentiated thyroid carcinoma［J］.Eur Thyroid J，2024，13（6）:e240225.DOI:10.1530/ETJ-24-0225.
［24］ Crouzeix G，Michels JJ，Sevin E，et al.Unusual short-term complete response to two regimens of cytotoxic chemotherapy in a patient with poorly differentiated thyroid carcinoma［J］.J Clin Endocrinol Metab，2012，97（9）:3046-3050.DOI:10.1210/jc.2012-1630.
［25］ Rosenbaum MW，Gigliotti BJ，Pai SI，et al.PD-L1 and IDO1 are expressed in poorly differentiated thyroid carcinoma［J］.Endocr Pathol，2018，29（1）:59-67.DOI:10.1007/s12022-018-9514-y.
［26］ Pałyga I，Rumian M，Kosel A，et al.The frequency of differentiated thyroid cancer recurrence in 2302 patients with excellent response to primary therapy［J］.J Clin Endocrinol Metab，2024，109（2）:e569-e578.DOI:10.1210/clinem/dgad571.
［27］ Walczyk A，Kopczyński J，Gąsior-Perczak D，et al.Histopathology and immunohistochemistry as prognostic factors for poorly differentiated thyroid cancer in a series of Polish patients［J］.PLoS One，2020，15（2）:e0229264.DOI:10.1371/journal.pone.0229264.
［28］ Xu B，David J，Dogan S，et al.Primary high-grade non-anaplastic thyroid carcinoma: A retrospective study of 364 cases［J］.Histopathology，2022，80（2）:322-337.DOI:10.1111/his.14550.
